A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease

Inclusion Criteria: * Diagnosis of mild-moderate Alzheimer disease (AD) * Mini-Mental State Examination (MMSE) 16-26 * Study partner available who has frequent contact with the participant * Good visual and auditory acuity for neuropsychological testing * Education including completion of at least six grades * Must read and speak English fluently * Antidepressants permitted, if stable for 4 weeks prior to screening (and participant is not currently depressed and does not have a history of major depression within the past 1 year) * Cholinesterase inhibitors permitted, if stable for 12 weeks prior to screening Exclusion Criteria: * Any significant neurologic disease other than AD * History of Diabetes Mellitus type I or II * Any contraindications to MRI or PET studies * Major depression, bipolar disorder as described within the past 1 year. * History of schizophrenia * History of alcohol or substance abuse or dependence within the past 2 years * Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol * Current use of specific psychoactive medications * Investigational amyloid lowering therapies are prohibited two months prior to screening and for the duration of the trial. Other investigational agents are prohibited one month prior to screening and for the duration of the trial. * History of brain cancer